BioSpace News Archive

Anixa Biosciences, Inc. today announced that the inventor of its ovarian cancer CAR-T technology, Dr. Jose Conejo-Garcia, has been invited to be the keynote speaker at Duke Cancer Institute’s Immuno-Oncology Research Program Retreat on November 4, 2022.

Isosceles Pharmaceuticals, Inc. has announced the execution of a non-binding letter of intent with a strategic partner for the phase 1 development of the Company’s intravenous product, IPI 201.

Gracell Biotechnologies Inc. today announced that it plans to release unaudited financial results for the third quarter ended September 30, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, November 14, 2022.

Verge Genomics announced today that the first subject has been dosed in a Phase 1 clinical trial of VRG50635. VRG50635 is a small molecule inhibitor of PIKfyve, a novel therapeutic target for amyotrophic lateral sclerosis (ALS) discovered by CONVERGETM, Verge’s all-in-human, AI-powered platform.

Alzamend Neuro, Inc. today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration (“FDA”) for a phase I/IIA clinical trial under its Investigational New Drug (“IND”) application for an immunotherapy (ALZN002) to treat mild to moderate dementia of the Alzheimer’s type.

The Loulou Foundation, a private foundation dedicated to the development of therapeutics for the neurodevelopmental condition CDKL5 Deficiency Disorder (CDD), announced today that the first patient has been enrolled in the three-year observational study with CDD patients, the Clinical Assessment of Neuro Developmental measures.

Sonnet BioTherapeutics Holdings, Inc. announced today a collaboration agreement with Janssen Biotech, Inc.

Ensysce Biosciences Inc. today announced positive topline results from a human abuse potential (HAP) study for PF614. PF614 is a new class of analgesia, a Trypsin Activated Abuse-Protected oxycodone product.

SpectronRx, a leading radiopharmaceutical contract development and manufacturing organization (CDMO), today announced that leading radiopharmaceutical executive Peter Webner has joined the company as Chief Operating Officer (COO).

Instil Bio, Inc. today announced that it has voluntarily paused enrollment in its ongoing clinical trials of ITIL-168 and ITIL-306 and has